Predicting cytomegalovirus viremia after liver or intestine transplantation (
Personalized Medicine For Better Health
-
15, Nov 2016
-
15, Nov 2016
Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) predict acute cellula
-
11, Sep 2014
PITTSBURGH, Sept. 11, 2014 /PRNewswire-iReach/ -- Today the FDA announced approval of PleximmuneTM -
27, Nov 2013
Prognostic cell-based assay predicts acute cellular rejection in pre- and post-transplant testing...
Chethan Ashokkumar1, Rafia Khan1, Kyle A. Soltys1,Geoffrey Bond1, George V. Mazariegos1, Brandon W. Higgs1, Rakesh Sindhi1 INSTITUTIONS (ALL): 1. Children's Hospital of Pgh of UPMC, Pittsburgh, PA, United States. -
11, Nov 2013
Novel antibody-drug conjugates (ADC), some with dual cellular targets, are re
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- - Assess disease risk for several immunological disorders.
- - Predict the success of a drug for a specific patient.
- - Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA